Nexalin launches Neurocare AI-driven virtual clinic for Alzheimer's, mood disorders, TBI, and PTSD
Summary
Nexalin Technology launched Neurocare — an AI-driven virtual clinic designed to transform access for patients with Alzheimer's, mood disorders, TBI, and PTSD — as reported in Neurotech Notables #47. Neurocare integrates Nexalin's DIFS neurostimulation protocols with AI-guided clinical decision support into a virtual care delivery model, enabling patients to receive neurostimulation therapy guidance without in-person specialist visits. The launch follows Nexalin's peer-reviewed publication showing DIFS improves attention and normalizes brain activity in ADHD, extending the platform into a broader set of neurological and psychiatric conditions.
Why it matters
Nexalin launching a virtual clinic extends their device-based therapy into a digital health delivery model — pivoting from a neuromodulation hardware company toward a care delivery platform. AI-guided virtual DIFS therapy delivery addresses the access barrier that limits neuromodulation adoption: patients in underserved areas cannot reach specialist TMS or DBS centers. A virtual model that delivers evidence-based neurostimulation guidance at scale creates a fundamentally different distribution channel than clinic-based device sales.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial